Interleukin-12 Based Therapy for Inflammatory Diseases

Tech ID: 95-05

Summary - Researchers from National Jewish Health have demonstrated in vivo in a murine model of asthma that administration of IL-12 is effective at substantially improving airway hyperresponsiveness.

Potential Applications - Therapy for respiratory diseases such as asthma

Advantages of Invention

  • IL-12 is a natural substance therefore decreasing the possibility of toxic side effects
  • IL-12 could be aerosolized

State of Development - Treatment of a murine model of asthma with IL-12 decreases airway hyperresponsiveness by 80%.

Further R&D Required - In vivo study in other animal models

Patent - US patent # 5,674,483

Inventors - Charles Irvin, PhD and Yuan-Po Tu, MD, DVM

Publication - Kodama et al. Clin Exp. Immunol. 2003 Feb 131(2):199-205

Licensing Status - This technology is available for licensing

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.